Yseop’s Post

Yseop continues to deploy and scale with bio pharmaceutical companies who are motivated to reduce time to market

Clinical trial analytics provides valuable insights into various aspects of clinical trials, while also reducing the errors commonly encountered in traditional trials. Read this blog to know how biopharmaceutical firms can leverage the power of analytics to optimize the trial process - https://bit.ly/46rFTAC #clinicaltrials #clinicalresearch #biopharma #drugdiscovery #drugdevelopment #regulatoryaffairs #healthcaredata #medicalaffairs #konectar

𝐀 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐆𝐮𝐢𝐝𝐞 𝐟𝐨𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 [𝐏𝐃𝐅 𝐆𝐮𝐢𝐝𝐞] 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲: https://lnkd.in/dpuaFFFz The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Expanding number of clinical trials along with robust investment in pharmaceutical R&D are some of the key driving factors of the market. Maximum number of pharmaceutical, biopharmaceutical, and medical device companies continue to make large investments to develop novel therapeutics and devices. The R&D-intensive nature of pharmaceutical industry, propels companies to outsource clinical trials for expediating launch of therapeutics to the market. The demand for clinical trial services is anticipated to increase as a result of the significant increase in clinical trials taking place around the world, which will subsequently fuel market expansion. As of June 2021, North America and Europe were home to the most clinical trials, according to the WHO's clinical trials registry. By February 2023, more than 30% of clinical trials had been registered in the US. Decentralized clinical trials have also become more common, rising by more than 25% in 2022. The decentralization of clinical trial components has significantly increased the volume of trials conducted annually.

Do you want to play a role in shaping the future of regulatory collaboration in Latin America? August is here and so is the new issue of the DIA Global Forum - with this very insightful article and call for action for Latin American regulators, from Silvia Bendiner and Belkis Romeu, for advancing biopharmaceutical innovation and patient access. A very relevant piece to support reflections around collaborative work among regulators in the region, specially from the regional reference authorities ANMAT Argentina, ANVISA Brazil, Invima Colombia, CECMED Cuba, ISP Chile, and COFEPRIS Mexico. I invite you to share this article with your network, and to help get it to regulators - and maybe influence the ongoing regional conversations about regulatory convergence and cooperation. #regulatory #convergence #worksharing #collaboration #innovation #latam https://lnkd.in/dxyen6ET